Search research articles
Contact Us
Filters
Showing results (51-60 of 66) with videos related to
Page
of 7
Sort By:
Cancers
|
August 27, 2021
Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic Drugs
Abed Agbarya, Ina Sarel, Tomer Ziv-Baran, et al.
Expert Opinion on Pharmacotherapy
|
February 4, 2026
Belzutifan monotherapy and combination therapies in renal cell carcinoma: a clinical trial perspective from the ARON working group
Concetta Calabrò, Francesco Ciccimarra, Alessandro Rizzo, et al.
Prostate Cancer and Prostatic Diseases
|
August 12, 2024
Select black men are potential candidates for prostate hemi-ablation based on radical prostatectomy histopathology for intermediate-risk prostate cancer-a multicenter SEARCH cohort study
Sriram Deivasigamani, Eric S Adams, Shannon Stock, et al.
The Journal of Clinical Investigation
|
April 1, 2026
Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers
Alec Paschalis, Ines Figueiredo, Denisa Bogdan, et al.
International Journal of Cancer
|
November 4, 2025
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)
Javier Molina-Cerrillo, Giandomenico Roviello, Maria T Bourlon, et al.
Frontiers in Immunology
|
March 12, 2026
Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?
Linda Cerbone, Giandomenico Roviello, Fabio Calabrò, et al.
Cancer Immunology, Immunotherapy : CII
|
May 9, 2025
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
Camillo Porta, Francesco Massari, Tarek Taha, et al.
European Urology Open Science
|
November 24, 2025
Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort
Ondrej Fiala, Francesco Grillone, Kazutoshi Fujita, et al.
European Urology Oncology
|
July 12, 2025
Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer
Sandra van Wilpe, Tarek Taha, Emily C Rothmann, et al.
Cancer Immunology, Immunotherapy : CII
|
March 24, 2026
Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)
Veronica Mollica, Francesco Massari, Kazutoshi Fujita, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 66) with videos related to
Sort By:
Page
of 7
Cancers
|
August 27, 2021
Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic Drugs
Abed Agbarya, Ina Sarel, Tomer Ziv-Baran, et al.
Expert Opinion on Pharmacotherapy
|
February 4, 2026
Belzutifan monotherapy and combination therapies in renal cell carcinoma: a clinical trial perspective from the ARON working group
Concetta Calabrò, Francesco Ciccimarra, Alessandro Rizzo, et al.
Prostate Cancer and Prostatic Diseases
|
August 12, 2024
Select black men are potential candidates for prostate hemi-ablation based on radical prostatectomy histopathology for intermediate-risk prostate cancer-a multicenter SEARCH cohort study
Sriram Deivasigamani, Eric S Adams, Shannon Stock, et al.
The Journal of Clinical Investigation
|
April 1, 2026
Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers
Alec Paschalis, Ines Figueiredo, Denisa Bogdan, et al.
International Journal of Cancer
|
November 4, 2025
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)
Javier Molina-Cerrillo, Giandomenico Roviello, Maria T Bourlon, et al.
Frontiers in Immunology
|
March 12, 2026
Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?
Linda Cerbone, Giandomenico Roviello, Fabio Calabrò, et al.
Cancer Immunology, Immunotherapy : CII
|
May 9, 2025
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
Camillo Porta, Francesco Massari, Tarek Taha, et al.
European Urology Open Science
|
November 24, 2025
Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort
Ondrej Fiala, Francesco Grillone, Kazutoshi Fujita, et al.
European Urology Oncology
|
July 12, 2025
Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer
Sandra van Wilpe, Tarek Taha, Emily C Rothmann, et al.
Cancer Immunology, Immunotherapy : CII
|
March 24, 2026
Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)
Veronica Mollica, Francesco Massari, Kazutoshi Fujita, et al.
Page
of 7